Last reviewed · How we verify

NCT06106282

Breast Cancer Survivors Who Experience Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS)

Completed Last updated 31 October 2025
What this trial tests

trial testing Non-Interventional Study in Anatomic Stage 0 Breast Cancer AJCC v8 in 105 participants. Completed in 27 October 2025.

Timeline
12 July 2023
Primary endpoint
27 October 2025
27 October 2025

Quick facts

Lead sponsorMayo Clinic
StatusCompleted
Study typeOBSERVATIONAL
Enrollment105
Start date12 July 2023
Primary completion27 October 2025
Estimated completion27 October 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Mayo Clinic

Who can join

18 and older, female only, with Anatomic Stage 0 Breast Cancer AJCC v8 or Anatomic Stage I Breast Cancer AJCC v8. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the effectiveness of a cognitive behavioral multicomponent treatment program in improving pain, mood, and functioning while reducing medication non-adherence in breast cancer patients with Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Non-Interventional Study

Trials testing the same drug.

Other recruiting trials for Anatomic Stage 0 Breast Cancer AJCC v8

Currently open trials in the same condition.

Other Mayo Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06106282.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing